Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 95 clinical trials
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

This will be a phase II single-arm clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based onmid-treatment tumor response. The primary objective of this study is to evaluate progression-free survival at 2 years.

serum pregnancy test
ct scan
hpv infection
formalin-fixed paraffin-embedded
  • 04 Oct, 2022
  • 1 location
p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT) (PROTEcT)

Volume and Dose De-Intensified Radiotherapy for p16+ Squamous Cell Carcinoma of the Oropharynx: A Multi-Centre, Single Arm Prospective Cohort Study

  • 04 Oct, 2022
  • 1 location
Induction Immunochemotherapy in Stage III-IVa Cancer of Oropharynx, Hypopharynx and Larynx

patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS>1 will recieve 3 cycles of induction immunochemotherapy with platinum, 5-FU and pembrolizumab followed by

  • 10 Oct, 2022
  • 1 location
Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC

Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and

  • 11 May, 2021
  • 1 location
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing

supportive care for locoregionally-advanced, HPV-related oropharyngeal cancer. Secondary purposes include comparison of total equivalent opioid dosage above baseline opioid use at end of treatment, quality

oropharyngeal cancer
  • 26 Feb, 2022
  • 1 location
Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA)

Following preliminary studies carried out in our department on these subject and subjective findings during clinical examinations, it has been shown that pain is a symptom that is rarely reported following treatment. Instead, neurosensory disorders such as hypoesthesia and paresthesia are found. The objective of the study is to map …

  • 27 Jan, 2021
  • 1 location
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

low risk human papilloma virus positive oropharyngeal cancer. This is an investigational study. MRI simulations and radiation therapy are delivered using FDA-approved and commercially available

oropharyngeal carcinoma
oropharyngeal squamous cell carcinoma
human papillomavirus
  • 05 Mar, 2022
  • 1 location
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

This study is being performed to evaluate the effectiveness of a new drug, clonidine HCl MBT, to prevent the onset of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) who

  • 20 Apr, 2021
  • 4 locations
A Prospective Single Arm Non-inferiority Trial of Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma (Major De-escalation to 30Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma)

The purpose of this study is to demonstrate that participants with HPV positive and hypoxia negative T1-2, N1-2c (AJCC, 7th ed.) oropharyngeal squamous cell carcinoma receiving a major de-escalated radiation therapy with 2 cycles of standard chemotherapy is not inferior to comparable subjects treated with the current standard chemoradiation. Accrual …

  • 25 Oct, 2022
  • 9 locations
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

In this study, participants will receive routine treatment with radiation therapy/RT if their HPV ctDNA levels rise after surgery. All participants will have their HPV ctDNA levels tested using a test made by a company called Naveris (the NavDx test).

  • 22 Apr, 2022
  • 6 locations